TerminatedPhase 2NCT01000155

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Studying Sickle cell anemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Maureen Okam, MD, MPH, MD
Brigham and Women's Hospital
Intervention
vorinostat(drug)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
2009 – 2014

Study locations (3)

Collaborators

Brigham and Women's Hospital · Boston Children's Hospital · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01000155 on ClinicalTrials.gov

Other trials for Sickle cell anemia

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell anemia →

← Back to all trials